Role of class II nuclear receptors in liver carcinogenesis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 529-542

  Li, Guodong ^a,b   Guo, Grace L ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Class II nuclear receptors; Constitutive androstane receptor; Farnesoid X receptor; Hepatocellular carcinoma; Liver X receptors; Peroxisome proliferator activated receptors; Pregnane X receptor; Retinoic acid receptors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLIN D1; CYCLOOXYGENASE 2; FARNESOID X RECEPTOR; GROWTH DIFFERENTIATION FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PREGNANE X RECEPTOR; PROTEIN BAD; PROTEIN P27; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID X RECEPTOR; ROSIGLITAZONE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG; VITAMIN D RECEPTOR;

CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; DISEASE COURSE; DNA BINDING; ENZYME ACTIVATION; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIVER CARCINOGENESIS; LIVER REGENERATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 79959287496     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796011064     Document Type: Review

References (246)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J., Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58 (2), 71-96.
2. Parkin, D. M., Global cancer statistics in the year 2000. Lancet Oncol., 2001, 2 (9), 533-543.
3. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55 (2), 74-108.
4. El-Serag, H. B.; Rudolph, K. L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132 (7), 2557-2576.
5. Gomaa, A. I.; Khan, S. A.; Toledano, M. B.; Waked, I.; Taylor-Robinson, S. D., Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 2008, 14 (27), 4300-4308.
6. Venook, A. P.; Papandreou, C.; Furuse, J.; de Guevara, L. L., The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist, 2010, 15 Suppl 4, 5-13.
7. Blonski, W.; Kotlyar, D. S.; Forde, K. A., Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol., 2010, 16 (29), 3603-3615.
8. Stickel, F.; Hellerbrand, C., Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut, 2010, 59 (10), 1303-1307.
9. Sherman, M., Epidemiology of hepatocellular carcinoma. Oncology, 2010, 78 Suppl 1, 7-10.
10. Yang, J. D.; Roberts, L. R., Hepatocellular carcinoma: A global view. Nat. Rev. Gastroenterol. Hepatol., 2010, 7 (8), 448-458.
11. Farazi, P. A.; DePinho, R. A., Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 2006, 6 (9), 674-687.
12. Aravalli, R. N.; Steer, C. J.; Cressman, E. N., Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48 (6), 2047-2063.
13. Llovet, J. M.; Bruix, J., Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48 (4), 1312-1327.
14. Lachenmayer, A.; Alsinet, C.; Chang, C. Y.; Llovet, J. M., Molecular approaches to treatment of hepatocellular carcinoma. Dig. Liver Dis., 2010, 42 Suppl 3, S264-272.
15. Minguez, B.; Tovar, V.; Chiang, D.; Villanueva, A.; Llovet, J. M., Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol., 2009, 25 (3), 186-194.
16. Villanueva, A.; Newell, P.; Chiang, D. Y.; Friedman, S. L.; Llovet, J. M., Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis., 2007, 27 (1), 55-76.
17. Wong, C. M.; Ng, I. O., Molecular pathogenesis of hepatocellular carcinoma. Liver Int., 2008, 28 (2), 160-174.
18. Whittaker, S.; Marais, R.; Zhu, A. X., The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29 (36), 4989-5005.
19. Zender, L.; Villanueva, A.; Tovar, V.; Sia, D.; Chiang, D. Y.; Llovet, J. M., Cancer gene discovery in hepatocellular carcinoma. J. Hepatol., 2010, 52 (6), 921-929.
20. Huang, S.; He, X., The role of microRNAs in liver cancer progression. Br. J. Cancer, 2011,104 (2), 235-240.
21. Bruix, J.; Sherman, M., Management of hepatocellular carcinoma. Hepatology, 2005, 42 (5), 1208-1236.
22. Llovet, J. M.; Burroughs, A.; Bruix, J., Hepatocellular carcinoma. Lancet, 2003, 362 (9399), 1907-1917.
23. Rossi, L.; Zoratto, F.; Papa, A.; Iodice, F.; Minozzi, M.; Frati, L.; Tomao, S., Current approach in the treatment of hepatocellular carcinoma. World J. Gastrointest. Oncol., 2010, 2 (9), 348-359.
24. Ye, S. L.; Takayama, T.; Geschwind, J.; Marrero, J. A.; Bronowicki, J. P., Current approaches to the treatment of early hepatocellular carcinoma. Oncologist, 2010, 15 Suppl 4, 34-41.
25. Poon, R. T.; Fan, S. T., Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl., 2004, 10 (2 Suppl 1), S39-45.
26. Hasegawa, K.; Kokudo, N.; Makuuchi, M., Surgical management of hepatocellular carcinoma. Liver resection and liver transplantation. Saudi Med. J., 2007, 28 (8), 1171-1179.
27. Hung, H. H.; Chiou, Y. Y.; Hsia, C. Y.; Su, C. W.; Chou, Y. H.; Chiang, J. H.; Kao, W. Y.; Huo, T. I.; Huang, Y. H.; Su, Y. H.; Lin, H. C.; Lee, S. D.; Wu, J. C., Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin. Gastroenterol. Hepatol., 2010, 9 (1), 79-86.
28. Saito, H.; Masuda, T.; Tada, S.; Ebinuma, H.; Yamagishi, Y.; Ojiro, K.; Inoue, M.; Hibi, T., Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease. Keio J. Med., 2009, 58 (3), 161-175.
29. Llovet, J. M.; Bruix, J., Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003, 37 (2), 429-442.
30. Lencioni, R.; Crocetti, L., A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. Clin. Liver Dis., 2005, 9 (2), 301-314, viii.
31. Bouza, C.; Lopez-Cuadrado, T.; Alcazar, R.; Saz-Parkinson, Z.; Amate, J. M., Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol., 2009, 9, 31.
32. Kudo, M., Radiofrequency ablation for hepatocellular carcinoma: updated review. Oncology, 2010, 78 Suppl 1, 113-124.
33. Liu, J. G.; Wang, Y. J.; Du, Z., Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis. World J. Gastroenterol., 2010, 16 (27), 3450-3456.
34. Biolato, M.; Marrone, G.; Racco, S.; Di Stasi, C.; Miele, L.; Gasbarrini, G.; Landolfi, R.; Grieco, A., Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur. Rev. Med. Pharmacol. Sci., 2010, 14 (4), 356-362.
35. Ierardi, E.; Rosania, R.; Zotti, M.; Giorgio, F.; Prencipe, S.; Valle, N. D.; Francesco, V. D.; Panella, C., From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways. World J. Gastrointest. Oncol., 2010, 2 (6), 259-264.
36. Maass, T.; Sfakianakis, I.; Staib, F.; Krupp, M.; Galle, P. R.; Teufel, A., Microarray-based gene expression analysis of hepatocellular carcinoma. Curr. Genomics, 2010, 11 (4), 261-268.
37. Severi, T.; van Malenstein, H.; Verslype, C.; van Pelt, J. F., Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol. Sin., 2010, 31 (11), 1409-1420.
38. Tanaka, S.; Arii, S., Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int. J. Clin. Oncol., 2010, 15 (3), 235-241.
39. Huynh, H., Molecularly targeted therapy in hepatocellular carcinoma. Biochem. Pharmacol., 2010, 80 (5), 550-560.
40. Li, T.; Wan, B.; Huang, J.; Zhang, X., Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration. Mol. Genet. Genomics, 2010, 283 (5), 485-492.
41. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J., Nuclear receptors and lipid physiology: opening the X-files. Science, 2001, 294 (5548), 1866-1870.
42. Francis, G. A.; Fayard, E.; Picard, F.; Auwerx, J., Nuclear receptors and the control of metabolism. Annu. Rev. Physiol., 2003, 65, 261-311.
43. McEwan, I. J., Nuclear receptors: one big family. Methods Mol. Biol., 2009, 505, 3-18.
44. Huang, P.; Chandra, V.; Rastinejad, F., Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol., 2010, 72, 247-272.
45. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M., The nuclear receptor superfamily: the second decade. Cell, 1995, 83 (6), 835-839.
46. Zhang, Z.; Burch, P. E.; Cooney, A. J.; Lanz, R. B.; Pereira, F. A.; Wu, J.; Gibbs, R. A.; Weinstock, G.; Wheeler, D. A., Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. Genome Res., 2004, 14 (4), 580-590.
47. Maglich, J. M.; Sluder, A.; Guan, X.; Shi, Y.; McKee, D. D.; Carrick, K.; Kamdar, K.; Willson, T. M.; Moore, J. T., Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol., 2001, 2 (8), RESEARCH0029.
48. Bookout, A. L.; Jeong, Y.; Downes, M.; Yu, R. T.; Evans, R. M.; Mangelsdorf, D. J., Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell, 2006, 126 (4), 789-799.
49. Yang, X.; Downes, M.; Yu, R. T.; Bookout, A. L.; He, W.; Straume, M.; Mangelsdorf, D. J.; Evans, R. M., Nuclear receptor expression links the circadian clock to metabolism. Cell, 2006, 126 (4), 801-810.
50. Barish, G. D.; Downes, M.; Alaynick, W. A.; Yu, R. T.; Ocampo, C. B.; Bookout, A. L.; Mangelsdorf, D. J.; Evans, R. M., A Nuclear Receptor Atlas: macrophage activation. Mol. Endocrinol., 2005, 19 (10), 2466-2477.
51. Stunnenberg, H. G., Mechanisms of transactivation by retinoic acid receptors. Bioessays, 1993, 15 (5), 309-315.
52. Ahmad, N.; Kumar, R., Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett., 2011, 300 (1), 1-9.
53. van Bilsen, M.; van Nieuwenhoven, F. A., PPARs as therapeutic targets in cardiovascular disease. Expert. Opin. Ther. Targets, 2010, 14 (10), 1029-1045.
54. Saijo, K.; Crotti, A.; Glass, C. K., Nuclear receptors, inflammation, and neurodegenerative diseases. Adv. Immunol., 2010, 106, 21-59.
55. Esser, C.; Rannug, A.; Stockinger, B., The aryl hydrocarbon receptor in immunity. Trends Immunol., 2009, 30 (9), 447-454.
56. Allred, D. C., Issues and updates: evaluating estrogen receptoralpha, progesterone receptor, and HER2 in breast cancer. Mod. Pathol., 2010, 23 Suppl 2, S52-59.
57. Hiukka, A.; Maranghi, M.; Matikainen, N.; Taskinen, M. R., PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat. Rev. Endocrinol., 2010, 6 (8), 454-463.
58. Zollner, G.; Wagner, M.; Trauner, M., Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther., 2010, 126 (3), 228-243.
59. Gyamfi, M. A.; Wan, Y. J., Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp. Biol. Med. (Maywood), 2010, 235 (5), 547-560.
60. Wagner, M.; Zollner, G.; Trauner, M., Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis., 2010, 30 (2), 160-177.
61. Gadaleta, R. M.; van Mil, S. W.; Oldenburg, B.; Siersema, P. D.; Klomp, L. W.; van Erpecum, K. J., Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim. Biophys. Acta, 2010, 1801 (7), 683-692.
62. Elfaki, D. A.; Bjornsson, E.; Lindor, K. D., Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications. Aliment. Pharmacol. Ther., 2009, 30 (8), 816-825.
63. Wei, J.; Qiu de, K.; Ma, X., Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J. Dig. Dis., 2009, 10 (2), 85-90.
64. Fiorucci, S.; Baldelli, F., Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol., 2009, 25 (3), 252-259.
65. Issemann, I.; Green, S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347 (6294), 645-650.
66. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W., Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, 68 (5), 879-887.
67. Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58 (4), 726-741.
68. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999, 97 (2), 161-163.
69. Michalik, L.; Desvergne, B.; Wahli, W., Peroxisome-proliferatoractivated receptors and cancers: complex stories. Nat. Rev. Cancer, 2004, 4 (1), 61-70.
70. Schoonjans, K.; Staels, B.; Auwerx, J., The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta, 1996, 1302 (2), 93-109.
71. Berger, J.; Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
72. Braissant, O.; Foufelle, F.; Scotto, C.; Dauca, M.; Wahli, W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, 137 (1), 354-366.
73. Kersten, S.; Seydoux, J.; Peters, J. M.; Gonzalez, F. J.; Desvergne, B.; Wahli, W., Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest., 1999, 103 (11), 1489-1498.
74. Gonzalez, F. J.; Peters, J. M.; Cattley, R. C., Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst., 1998, 90 (22), 1702-1709.
75. Lee, S. S.; Pineau, T.; Drago, J.; Lee, E. J.; Owens, J. W.; Kroetz, D. L.; Fernandez-Salguero, P. M.; Westphal, H.; Gonzalez, F. J., Targeted disruption of the alpha isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol., 1995, 15 (6), 3012-3022.
76. Peters, J. M.; Cattley, R. C.; Gonzalez, F. J., Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis, 1997, 18 (11), 2029-2033.
77. Morimura, K.; Cheung, C.; Ward, J. M.; Reddy, J. K.; Gonzalez, F. J., Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis, 2006, 27 (5), 1074-1080.
78. Palmer, C. N.; Hsu, M. H.; Griffin, K. J.; Raucy, J. L.; Johnson, E. F., Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol., 1998, 53 (1), 14-22.
79. Walgren, J. E.; Kurtz, D. T.; McMillan, J. M., Expression of PPAR(alpha) in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun. Mol. Pathol. Pharmacol., 2000, 108 (1-2), 116-132.
80. Peters, J. M.; Cheung, C.; Gonzalez, F. J., Peroxisome proliferatoractivated receptor-alpha and liver cancer: where do we stand? J. Mol. Med., 2005, 83 (10), 774-785.
81. Fidaleo, M., Human health risk assessment for peroxisome proliferators: more than 30 years of research. Exp. Toxicol. Pathol., 2009, 61 (3), 215-221.
82. Parzefall, W.; Berger, W.; Kainzbauer, E.; Teufelhofer, O.; Schulte-Hermann, R.; Thurman, R. G., Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. Carcinogenesis, 2001, 22 (3), 519-523.
83. Reddy, J. K., Peroxisome proliferators and peroxisome proliferatoractivated receptor alpha: biotic and xenobiotic sensing. Am. J. Pathol., 2004, 164 (6), 2305-2321.
84. Roberts, R. A., Evidence for cross talk between PPARalpha and p38 MAP kinase. Toxicol. Sci., 2002, 68 (2), 270-274.
85. Bosgra, S.; Mennes, W.; Seinen, W., Proceedings in uncovering the mechanism behind peroxisome proliferator-induced hepatocarcinogenesis. Toxicology, 2005, 206 (3), 309-323.
86. Rose, M. L.; Rusyn, I.; Bojes, H. K.; Belyea, J.; Cattley, R. C.; Thurman, R. G., Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat. Res., 2000, 448 (2), 179-192.
87. Chen, H. H.; Sue, Y. M.; Chen, C. H.; Hsu, Y. H.; Hou, C. C.; Cheng, C. Y.; Lin, S. L.; Tsai, W. L.; Chen, T. W.; Chen, T. H., Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol. Dial. Transplant., 2009, 24 (10), 3042-3049.
88. Shah, Y. M.; Morimura, K.; Yang, Q.; Tanabe, T.; Takagi, M.; Gonzalez, F. J., Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell Biol., 2007, 27 (12), 4238-4247.
89. Desvergne, B.; Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20 (5), 649-688.
90. Shearer, B. G.; Hoekstra, W. J., Recent advances in peroxisome proliferator-activated receptor science. Curr. Med. Chem., 2003, 10 (4), 267-280.
91. Evans, R. M.; Barish, G. D.; Wang, Y. X., PPARs and the complex journey to obesity. Nat. Med., 2004, 10 (4), 355-361.
92. Wu, C. W.; Yu, J.; Sung, J. J., Peroxisome proliferator-activated receptor delta and gastric cancer (Review). Oncol. Rep., 2009, 22 (3), 451-457.
93. Wagner, K. D.; Wagner, N., Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol. Ther., 2010, 125 (3), 423-435.
94. Lee, C. H.; Olson, P.; Hevener, A.; Mehl, I.; Chong, L. W.; Olefsky, J. M.; Gonzalez, F. J.; Ham, J.; Kang, H.; Peters, J. M.; Evans, R. M., PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. USA, 2006, 103 (9), 3444-3449.
95. Coll, T.; Rodriguez-Calvo, R.; Barroso, E.; Serrano, L.; Eyre, E.; Palomer, X.; Vazquez-Carrera, M., Peroxisome proliferatoractivated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. Curr. Mol. Pharmacol., 2009, 2 (1), 46-55.
96. Peters, J. M.; Gonzalez, F. J., Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/ delta) in cell proliferation and cancer. Biochim. Biophys. Acta, 2009, 1796 (2), 230-241.
97. Peters, J. M.; Hollingshead, H. E.; Gonzalez, F. J., Role of peroxisome- proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin. Sci. (Lond), 2008, 115 (4), 107-127.
98. Glinghammar, B.; Skogsberg, J.; Hamsten, A.; Ehrenborg, E., PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun., 2003, 308 (2), 361-368.
99. Xu, L.; Han, C.; Lim, K.; Wu, T., Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res., 2006, 66 (24), 11859-11868.
100. Xu, L.; Han, C.; Wu, T., A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem., 2006, 281 (45), 33982-33996.
101. Hollingshead, H. E.; Killins, R. L.; Borland, M. G.; Girroir, E. E.; Billin, A. N.; Willson, T. M.; Sharma, A. K.; Amin, S.; Gonzalez, F. J.; Peters, J. M., Peroxisome proliferator-activated receptorbeta/ delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis, 2007, 28 (12), 2641-2649.
102. Shan, W.; Nicol, C. J.; Ito, S.; Bility, M. T.; Kennett, M. J.; Ward, J. M.; Gonzalez, F. J.; Peters, J. M., Peroxisome proliferatoractivated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology, 2008, 47 (1), 225-235.
103. Kino, T.; Rice, K. C.; Chrousos, G. P., The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest., 2007, 37 (5), 425-433.
104. Bishop-Bailey, D.; Bystrom, J., Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol. Ther., 2009, 124 (2), 141-150.
105. Nagasawa, T.; Inada, Y.; Nakano, S.; Tamura, T.; Takahashi, T.; Maruyama, K.; Yamazaki, Y.; Kuroda, J.; Shibata, N., Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionineand choline-deficient diet. Eur. J. Pharmacol., 2006, 536 (1-2), 182-191.
106. Qin, X.; Xie, X.; Fan, Y.; Tian, J.; Guan, Y.; Wang, X.; Zhu, Y.; Wang, N., Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology, 2008, 48 (2), 432-441.
107. Shan, W.; Palkar, P. S.; Murray, I. A.; McDevitt, E. I.; Kennett, M. J.; Kang, B. H.; Isom, H. C.; Perdew, G. H.; Gonzalez, F. J.; Peters, J. M., Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci., 2008, 105 (2), 418-428.
108. Zhu, Y.; Alvares, K.; Huang, Q.; Rao, M. S.; Reddy, J. K., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem, 1993, 268 (36), 26817-26820.
109. Kliewer, S. A.; Umesono, K.; Mangelsdorf, D. J.; Evans, R. M., Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature, 1992, 355 (6359), 446-449.
110. Chawla, A.; Schwarz, E. J.; Dimaculangan, D. D.; Lazar, M. A., Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 1994, 135 (2), 798-800.
111. Tontonoz, P.; Hu, E.; Spiegelman, B. M., Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell, 1994, 79 (7), 1147-1156.
112. Nahle, Z., PPAR trilogy from metabolism to cancer. Curr Opin Clin. Nutr. Metab. Care, 2004, 7 (4), 397-402.
113. Auboeuf, D.; Rieusset, J.; Fajas, L.; Vallier, P.; Frering, V.; Riou, J. P.; Staels, B.; Auwerx, J.; Laville, M.; Vidal, H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes, 1997, 46 (8), 1319-1327.
114. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K.; Lefebvre, A. M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J. C.; Deeb, S.; Vidal- Puig, A.; Flier, J.; Briggs, M. R.; Staels, B.; Vidal, H.; Auwerx, J., The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 1997, 272 (30), 18779-18789.
115. Fajas, L.; Fruchart, J. C.; Auwerx, J., PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett., 1998, 438 (1-2), 55-60.
116. Sundvold, H.; Lien, S., Identification of a novel peroxisome proliferator- activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys. Res. Commun., 2001, 287 (2), 383-390.
117. Vamecq, J.; Latruffe, N., Medical significance of peroxisome proliferator-activated receptors. Lancet, 1999, 354 (9173), 141-148.
118. Zieleniak, A.; Wojcik, M.; Wozniak, L. A., Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch. Immunol. Ther. Exp. (Warsz), 2008, 56 (5), 331-345.
119. Rangwala, S. M.; Lazar, M. A., Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci., 2004, 25 (6), 331-336.
120. Chinetti, G.; Fruchart, J. C.; Staels, B., Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 2000, 49 (10), 497-505.
121. Lehrke, M.; Lazar, M. A., The many faces of PPARgamma. Cell, 2005, 123 (6), 993-999.
122. Tontonoz, P.; Spiegelman, B. M., Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem., 2008, 77, 289-312.
123. Kapadia, R.; Yi, J. H.; Vemuganti, R., Mechanisms of antiinflammatory and neuroprotective actions of PPAR-gamma agonists. Front. Biosci., 2008, 13, 1813-1826.
124. Voutsadakis, I. A., Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J. Cancer Res. Clin. Oncol., 2007, 133 (12), 917-928.
125. Mansure, J. J.; Nassim, R.; Kassouf, W., Peroxisome proliferatoractivated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol. Ther., 2009, 8 (7), 6-15.
126. Wang, T.; Xu, J.; Yu, X.; Yang, R.; Han, Z. C., Peroxisome proliferator- activated receptor gamma in malignant diseases. Crit. Rev. Oncol. Hematol., 2006, 58 (1), 1-14.
127. Ondrey, F., Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin. Cancer Res., 2009, 15 (1), 2-8.
128. Murphy, G. J.; Holder, J. C., PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci., 2000, 21 (12), 469-474.
129. Bull, A. W., The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch. Pathol. Lab. Med., 2003, 127 (9), 1121-1123.
130. Konturek, P. C.; Kania, J.; Konturek, J. W.; Nikiforuk, A.; Konturek, S. J.; Hahn, E. G., H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis. Med. Sci. Monit., 2003, 9 (7), SR53-66.
131. Gavrilova, O.; Haluzik, M.; Matsusue, K.; Cutson, J. J.; Johnson, L.; Dietz, K. R.; Nicol, C. J.; Vinson, C.; Gonzalez, F. J.; Reitman, M. L., Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem., 2003, 278 (36), 34268-34276.
132. Koga, H.; Sakisaka, S.; Harada, M.; Takagi, T.; Hanada, S.; Taniguchi, E.; Kawaguchi, T.; Sasatomi, K.; Kimura, R.; Hashimoto, O.; Ueno, T.; Yano, H.; Kojiro, M.; Sata, M., Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazoneinduced cell-cycle arrest in human hepatoma cell lines. Hepatology, 2001, 33 (5), 1087-1097.
133. Yoshizawa, K.; Cioca, D. P.; Kawa, S.; Tanaka, E.; Kiyosawa, K., Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer, 2002, 95 (10), 2243-2251.
134. Rumi, M. A.; Sato, H.; Ishihara, S.; Kawashima, K.; Hamamoto, S.; Kazumori, H.; Okuyama, T.; Fukuda, R.; Nagasue, N.; Kinoshita, Y., Peroxisome proliferator-activated receptor gamma ligandinduced growth inhibition of human hepatocellular carcinoma. Br J Cancer, 2001, 84 (12), 1640-1647.
135. Shim, J.; Kim, B. H.; Kim, Y. I.; Kim, K. Y.; Hwangbo, Y.; Jang, J. Y.; Dong, S. H.; Kim, H. J.; Chang, Y. W.; Chang, R., The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. Int. J. Oncol., 2010, 36 (1), 223-231.
136. Toyoda, M.; Takagi, H.; Horiguchi, N.; Kakizaki, S.; Sato, K.; Takayama, H.; Mori, M., A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut, 2002, 50 (4), 563-567.
137. Sharma, C.; Pradeep, A.; Pestell, R. G.; Rana, B., Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J. Biol. Chem., 2004, 279 (17), 16927-16938.
138. Sharma, C.; Pradeep, A.; Wong, L.; Rana, A.; Rana, B., Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J. Biol. Chem., 2004, 279 (34), 35583-35594.
139. Mishra, P.; Paramasivam, S. K.; Thylur, R. P.; Rana, A.; Rana, B., Peroxisome proliferator-activated receptor gamma ligandmediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. J. Mol. Signal. 2010, 5, 20.
140. Li, M. Y.; Deng, H.; Zhao, J. M.; Dai, D.; Tan, X. Y., PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J. Gastroenterol., 2003, 9 (6), 1220-1226.
141. Date, M.; Fukuchi, K.; Morita, S.; Takahashi, H.; Ohura, K., 15- Deoxy-delta12,14-prostaglandin J2, a ligand for peroxisome proliferators- activated receptor-gamma, induces apoptosis in human hepatoma cells. Liver Int., 2003, 23 (6), 460-466.
142. Li, M. Y.; Deng, H.; Zhao, J. M.; Dai, D.; Tan, X. Y., Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. World J. Gastroenterol., 2003, 9 (8), 1683-1688.
143. Okano, H.; Shiraki, K.; Inoue, H.; Yamanaka, T.; Deguchi, M.; Sugimoto, K.; Sakai, T.; Ohmori, S.; Fujikawa, K.; Murata, K.; Nakano, T., Peroxisome proliferator-activated receptor gamma augments tumor necrosis factor family-induced apoptosis in hepatocellular carcinoma. Anticancer Drugs, 2002, 13 (1), 59-65.
144. Zhang, W.; Wu, N.; Li, Z.; Wang, L.; Jin, J.; Zha, X. L., PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol. Ther., 2006, 5 (8), 1008-1014.
145. Cao, L. Q.; Wang, X. L.; Wang, Q.; Xue, P.; Jiao, X. Y.; Peng, H. P.; Lu, H. W.; Zheng, Q.; Chen, X. L.; Huang, X. H.; Fu, X. H.; Chen, J. S., Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. Acta Pharmacol. Sin., 2009, 30 (9), 1316-1322.
146. Giuliano, M.; Pellerito, O.; Portanova, P.; Calvaruso, G.; Santulli, A.; De Blasio, A.; Vento, R.; Tesoriere, G., Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie, 2009, 91 (4), 457-465.
147. Han, C.; Bowen, W. C.; Li, G.; Demetris, A. J.; Michalopoulos, G. K.; Wu, T., Cytosolic phospholipase A2alpha and peroxisome proliferator- activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth. Hepatology, 2010, 52 (2), 644-655.
148. Guo, Y. T.; Leng, X. S.; Li, T.; Zhao, J. M.; Lin, X. H., Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats. World J. Gastroenterol., 2004, 10 (23), 3419-3423.
149. Borbath, I.; Leclercq, I.; Moulin, P.; Sempoux, C.; Horsmans, Y., The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer, 2007, 43 (11), 1755-1763.
150. Yu, J.; Qiao, L.; Zimmermann, L.; Ebert, M. P.; Zhang, H.; Lin, W.; Rocken, C.; Malfertheiner, P.; Farrell, G. C., Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology, 2006, 43 (1), 134-143.
151. Hsu, M. C.; Huang, C. C.; Chang, H. C.; Hu, T. H.; Hung, W. C., Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Clin. Cancer Res., 2008, 14 (13), 4045-4052.
152. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 1995, 270 (22), 12953-12956.
153. Leahy, J. L., Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. Curr. Diab. Rep., 2009, 9 (3), 215-220.
154. Galli, A.; Ceni, E.; Mello, T.; Polvani, S.; Tarocchi, M.; Buccoliero, F.; Lisi, F.; Cioni, L.; Ottanelli, B.; Foresta, V.; Mastrobuoni, G.; Moneti, G.; Pieraccini, G.; Surrenti, C.; Milani, S., Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virustransgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Hepatology, 2010, 52 (2), 493-505.
155. Petrovic, V.; Costa, R. H.; Lau, L. F.; Raychaudhuri, P.; Tyner, A. L., Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol. Ther. 2010, 9 (12), 1008-1016.
156. Takano, S.; Kubota, T.; Nishibori, H.; Hasegawa, H.; Ishii, Y.; Nitori, N.; Ochiai, H.; Okabayashi, K.; Kitagawa, Y.; Watanabe, M.; Kitajima, M., Pioglitazone, a ligand for peroxisome proliferator- activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res., 2008, 28 (6A), 3593-3599.
157. Schaefer, K. L.; Wada, K.; Takahashi, H.; Matsuhashi, N.; Ohnishi, S.; Wolfe, M. M.; Turner, J. R.; Nakajima, A.; Borkan, S. C.; Saubermann, L. J., Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res., 2005, 65 (6), 2251-2259.
158. Kim, K. R.; Choi, H. N.; Lee, H. J.; Baek, H. A.; Park, H. S.; Jang, K. Y.; Chung, M. J.; Moon, W. S., A peroxisome proliferatoractivated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol. Rep., 2007, 18 (4), 825-832.
159. Yu, J.; Shen, B.; Chu, E. S.; Teoh, N.; Cheung, K. F.; Wu, C. W.; Wang, S.; Lam, C. N.; Feng, H.; Zhao, J.; Cheng, A. S.; To, K. F.; Chan, H. L.; Sung, J. J., Inhibitory role of peroxisome proliferatoractivated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology, 2010, 51 (6), 2008-2019.
160. Chambon, P., A decade of molecular biology of retinoic acid receptors. FASEB J., 1996, 10 (9), 940-954.
161. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H., International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev., 2006, 58 (4), 712-725.
162. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H., International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev., 2006, 58 (4), 760-772.
163. Rochette-Egly, C.; Germain, P., Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl. Recept. Signal., 2009, 7, e005.
164. Sano, K.; Takayama, T.; Murakami, K.; Saiki, I.; Makuuchi, M., Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin. Cancer Res., 2003, 9 (10 Pt 1), 3679-3683.
165. Murakami, K.; Matsuura, T.; Hasumura, S.; Nagamori, S.; Yamada, Y.; Saiki, I., Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. Cancer Lett., 2000, 151 (1), 63-70.
166. Ledda-Columbano, G. M.; Pibiri, M.; Molotzu, F.; Cossu, C.; Sanna, L.; Simbula, G.; Perra, A.; Columbano, A., Induction of hepatocyte proliferation by retinoic acid. Carcinogenesis, 2004, 25 (11), 2061-2066.
167. Di Bisceglie, A. M.; Osmack, P.; Brunt, E. M., Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesis. J Lab Clin Med, 2005, 145 (3), 134-138.
168. Allton, K.; Jain, A. K.; Herz, H. M.; Tsai, W. W.; Jung, S. Y.; Qin, J.; Bergmann, A.; Johnson, R. L.; Barton, M. C., Trim24 targets endogenous p53 for degradation. Proc. Natl. Acad. Sci. USA, 2009, 106 (28), 11612-11616.
169. Khetchoumian, K.; Teletin, M.; Tisserand, J.; Mark, M.; Herquel, B.; Ignat, M.; Zucman-Rossi, J.; Cammas, F.; Lerouge, T.; Thibault, C.; Metzger, D.; Chambon, P.; Losson, R., Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat. Genet., 2007, 39 (12), 1500-1506.
170. Khetchoumian, K.; Teletin, M.; Tisserand, J.; Herquel, B.; Ouararhni, K.; Losson, R., Trim24 (Tif1 alpha): an essential 'brake' for retinoic acid-induced transcription to prevent liver cancer. Cell Cycle, 2008, 7 (23), 3647-3652.
171. Yanagitani, A.; Yamada, S.; Yasui, S.; Shimomura, T.; Murai, R.; Murawaki, Y.; Hashiguchi, K.; Kanbe, T.; Saeki, T.; Ichiba, M.; Tanabe, Y.; Yoshida, Y.; Morino, S.; Kurimasa, A.; Usuda, N.; Yamazaki, H.; Kunisada, T.; Ito, H.; Shiota, G., Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology, 2004, 40 (2), 366-375.
172. Shiota, G., Role of retinoic acid receptor in steatohepatitis-related tumor formation. J. Gastroenterol. Hepatol., 2007, 22 Suppl 1, S101-107.
173. Li, M.; Li, H.; Li, C.; Guo, L.; Liu, H.; Zhou, S.; Liu, X.; Chen, Z.; Shi, S.; Wei, J.; McNutt, M. A.; Li, G., Cytoplasmic alphafetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett., 2009, 285 (2), 190-199.
174. Bu, P.; Wan, Y. J., Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer, 2007, 7, 236.
175. Li, C.; Wan, Y. J., Differentiation and antiproliferation effects of retinoic acid receptor beta in hepatoma cells. Cancer Lett., 1998, 124 (2), 205-211.
176. Yang, B.; Guo, M.; Herman, J. G.; Clark, D. P., Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol., 2003, 163 (3), 1101-1107.
177. Jung, J. K.; Park, S. H.; Jang, K. L., Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by downregulating retinoic acid receptor-beta2 expression via DNA methylation. J. Gen. Virol., 2010, 91 (Pt 2), 493-500.
178. Yan, T. D.; Wu, H.; Zhang, H. P.; Lu, N.; Ye, P.; Yu, F. H.; Zhou, H.; Li, W. G.; Cao, X.; Lin, Y. Y.; He, J. Y.; Gao, W. W.; Zhao, Y.; Xie, L.; Chen, J. B.; Zhang, X. K.; Zeng, J. Z., Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res., 2010, 70 (6), 2285-2295.
179. Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.; Perlmann, T.; Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W. W.; Evans, R. M.; Weinberger, C., Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81 (5), 687-693.
180. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B., Identification of a nuclear receptor for bile acids. Science, 1999, 284 (5418), 1362-1365.
181. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M., Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284 (5418), 1365-1368.
182. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M., Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell, 1999, 3 (5), 543-553.
183. Laffitte, B. A.; Kast, H. R.; Nguyen, C. M.; Zavacki, A. M.; Moore, D. D.; Edwards, P. A., Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem., 2000, 275 (14), 10638-10647.
184. Zhang, Y.; Edwards, P. A., FXR signaling in metabolic disease. FEBS Lett, 2008, 582 (1), 10-18.
185. Chen, W. D.; Wang, Y. D.; Meng, Z.; Zhang, L.; Huang, W., Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim. Biophys. Acta, 2010.
186. Lee, F. Y.; Lee, H.; Hubbert, M. L.; Edwards, P. A.; Zhang, Y., FXR, a multipurpose nuclear receptor. Trends Biochem. Sci., 2006, 31 (10), 572-580.
187. Wang, Y. D.; Chen, W. D.; Moore, D. D.; Huang, W., FXR: a metabolic regulator and cell protector. Cell Res., 2008, 18 (11), 1087-1095.
188. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J. M.; Gonzalez, F. J., Spontaneous hepatocarcinogenesis in farnesoid X receptornull mice. Carcinogenesis, 2007, 28 (5), 940-946.
189. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D. D.; Huang, W., Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res., 2007, 67 (3), 863-867.
190. Thomas, A. M.; Hart, S. N.; Kong, B.; Fang, J.; Zhong, X. B.; Guo, G. L., Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology, 2010, 51 (4), 1410-1419.
191. Wang, Y. D.; Chen, W. D.; Wang, M.; Yu, D.; Forman, B. M.; Huang, W., Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology, 2008, 48 (5), 1632-1643.
192. Baes, M.; Gulick, T.; Choi, H. S.; Martinoli, M. G.; Simha, D.; Moore, D. D., A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell Biol., 1994, 14 (3), 1544-1552.
193. di Masi, A.; De Marinis, E.; Ascenzi, P.; Marino, M., Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol. Aspects Med., 2009, 30 (5), 297-343.
194. Wada, T.; Gao, J.; Xie, W., PXR and CAR in energy metabolism. Trends Endocrinol. Metab., 2009, 20 (6), 273-279.
195. Diwan, B. A.; Lubet, R. A.; Ward, J. M.; Hrabie, J. A.; Rice, J. M., Tumor-promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5- dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine. Carcinogenesis, 1992, 13 (10), 1893-1901.
196. Whysner, J.; Ross, P. M.; Williams, G. M., Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther., 1996, 71 (1-2), 153-191.
197. Huang, W.; Zhang, J.; Washington, M.; Liu, J.; Parant, J. M.; Lozano, G.; Moore, D. D., Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol., 2005, 19 (6), 1646-1653.
198. Yamamoto, Y.; Moore, R.; Goldsworthy, T. L.; Negishi, M.; Maronpot, R. R., The orphan nuclear receptor constitutive active/ androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res., 2004, 64 (20), 7197-7200.
199. Blanco-Bose, W. E.; Murphy, M. J.; Ehninger, A.; Offner, S.; Dubey, C.; Huang, W.; Moore, D. D.; Trumpp, A., C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology, 2008, 48 (4), 1302-1311.
200. Phillips, J. M.; Yamamoto, Y.; Negishi, M.; Maronpot, R. R.; Goodman, J. I., Orphan nuclear receptor constitutive active/ androstane receptor-mediated alterations in DNA methylation during phenobarbital promotion of liver tumorigenesis. Toxicol. Sci., 2007, 96 (1), 72-82.
201. Phillips, J. M.; Goodman, J. I., Multiple genes exhibit phenobarbital- induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. Toxicol. Sci., 2009, 108 (2), 273-289.
202. Phillips, J. M.; Burgoon, L. D.; Goodman, J. I., The constitutive active/androstane receptor facilitates unique phenobarbitalinduced expression changes of genes involved in key pathways in precancerous liver and liver tumors. Toxicol. Sci., 2009, 110 (2), 319-333.
203. Ross, J.; Plummer, S. M.; Rode, A.; Scheer, N.; Bower, C. C.; Vogel, O.; Henderson, C. J.; Wolf, C. R.; Elcombe, C. R., Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol Sci., 2010, 116 (2), 452-466.
204. Page, J. L.; Strom, S. C.; Omiecinski, C. J., Regulation of the human cathepsin E gene by the constitutive androstane receptor. Arch. Biochem. Biophys., 2007, 467 (1), 132-138.
205. Pascussi, J. M.; Robert, A.; Moreau, A.; Ramos, J.; Bioulac-Sage, P.; Navarro, F.; Blanc, P.; Assenat, E.; Maurel, P.; Vilarem, M. J., Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. Hepatology, 2007, 45 (5), 1146-1153.
206. Kliewer, S. A.; Moore, J. T.; Wade, L.; Staudinger, J. L.; Watson, M. A.; Jones, S. A.; McKee, D. D.; Oliver, B. B.; Willson, T. M.; Zetterstrom, R. H.; Perlmann, T.; Lehmann, J. M., An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 1998, 92 (1), 73-82.
207. Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C. M.; Ong, E. S.; Evans, R. M., SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev., 1998, 12 (20), 3195-3205.
208. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A., Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci USA, 1998, 95 (21), 12208-12213.
209. Bauer, B.; Hartz, A. M.; Fricker, G.; Miller, D. S., Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol., 2004, 66 (3), 413-419.
210. Lamba, J. K.; Lamba, V.; Yasuda, K.; Lin, Y. S.; Assem, M.; Thompson, E.; Strom, S.; Schuetz, E., Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J. Pharmacol. Exp. Ther., 2004, 311 (2), 811-821.
211. Lamba, V.; Yasuda, K.; Lamba, J. K.; Assem, M.; Davila, J.; Strom, S.; Schuetz, E. G., PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol., 2004, 199 (3), 251-265.
212. Rosenfeld, J. M.; Vargas, R., Jr.; Xie, W.; Evans, R. M., Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol., 2003, 17 (7), 1268-1282.
213. Zhang, B.; Xie, W.; Krasowski, M. D., PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics, 2008, 9 (11), 1695-1709.
214. Zhou, C.; Verma, S.; Blumberg, B., The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl. Recept. Signal., 2009, 7, e001.
215. Matic, M.; Mahns, A.; Tsoli, M.; Corradin, A.; Polly, P.; Robertson, G. R., Pregnane X receptor: promiscuous regulator of detoxification pathways. Int. J. Biochem. Cell Biol., 2007, 39 (3), 478-483.
216. Zhou, J.; Zhai, Y.; Mu, Y.; Gong, H.; Uppal, H.; Toma, D.; Ren, S.; Evans, R. M.; Xie, W., A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem., 2006, 281 (21), 15013-15020.
217. Moya, M.; Gomez-Lechon, M. J.; Castell, J. V.; Jover, R., Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem. Biol. Interact., 2010, 184 (3), 376-387.
218. Zhou, J.; Febbraio, M.; Wada, T.; Zhai, Y.; Kuruba, R.; He, J.; Lee, J. H.; Khadem, S.; Ren, S.; Li, S.; Silverstein, R. L.; Xie, W., Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology, 2008, 134 (2), 556-567.
219. Sookoian, S.; Castano, G. O.; Burgueno, A. L.; Gianotti, T. F.; Rosselli, M. S.; Pirola, C. J., The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics, 2010, 20 (1), 1-8.
220. Janowski, B. A.; Willy, P. J.; Devi, T. R.; Falck, J. R.; Mangelsdorf, D. J., An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature, 1996, 383 (6602), 728-731.
221. Janowski, B. A.; Grogan, M. J.; Jones, S. A.; Wisely, G. B.; Kliewer, S. A.; Corey, E. J.; Mangelsdorf, D. J., Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A, 1999, 96 (1), 266-271.
222. Willy, P. J.; Umesono, K.; Ong, E. S.; Evans, R. M.; Heyman, R. A.; Mangelsdorf, D. J., LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev., 1995, 9 (9), 1033-1045.
223. Zhao, C.; Dahlman-Wright, K., Liver X receptor in cholesterol metabolism. J. Endocrinol., 2010, 204 (3), 233-240.
224. Jamroz-Wisniewska, A.; Wojcicka, G.; Horoszewicz, K.; Beltowski, J., Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy. Hig. Med. Dosw (Online), 2007, 61, 760-785.
225. Moriishi, K.; Mochizuki, R.; Moriya, K.; Miyamoto, H.; Mori, Y.; Abe, T.; Murata, S.; Tanaka, K.; Miyamura, T.; Suzuki, T.; Koike, K.; Matsuura, Y., Critical role of PA28gamma in hepatitis C virusassociated steatogenesis and hepatocarcinogenesis. Proc Natl. Acad. Sci. USA, 2007, 104 (5), 1661-1666.
226. Na, T. Y.; Shin, Y. K.; Roh, K. J.; Kang, S. A.; Hong, I.; Oh, S. J.; Seong, J. K.; Park, C. K.; Choi, Y. L.; Lee, M. O., Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology, 2009, 49 (4), 1122-1131.
227. Gabbi, C.; Kim, H. J.; Barros, R.; Korach-Andre, M.; Warner, M.; Gustafsson, J. A., Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/- female mice. Proc. Natl. Acad. Sci. USA, 2010, 107 (33), 14763-14768.
228. Harvey, C. B.; Williams, G. R., Mechanism of thyroid hormone action. Thyroid, 2002, 12 (6), 441-446.
229. Yen, P. M., Physiological and molecular basis of thyroid hormone action. Physiol Rev., 2001, 81 (3), 1097-1142.
230. Zhang, J.; Lazar, M. A., The mechanism of action of thyroid hormones. Annu. Rev. Physiol., 2000, 62, 439-466.
231. Cheng, S. Y., Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev. Endocr. Metab. Disord., 2000, 1 (1-2), 9-18.
232. Lin, K. H.; Shieh, H. Y.; Chen, S. L.; Hsu, H. C., Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol. Carcinog., 1999, 26 (1), 53-61.
233. Lin, K. H.; Zhu, X. G.; Hsu, H. C.; Chen, S. L.; Shieh, H. Y.; Chen, S. T.; McPhie, P.; Cheng, S. Y., Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma. Endocrinology, 1997, 138 (12), 5308-5315.
234. Chan, I. H.; Privalsky, M. L., Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene, 2006, 25 (25), 3576-3588.
235. Chan, I. H.; Privalsky, M. L., Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire. Oncogene, 2009, 28 (47), 4162-4174.
236. Chan, I. H.; Privalsky, M. L., A conserved lysine in the thyroid hormone receptor-alpha1 DNA-binding domain, mutated in hepatocellular carcinoma, serves as a sensor for transcriptional regulation. Mol. Cancer Res., 2010, 8 (1), 15-23.
237. Yen, C. C.; Huang, Y. H.; Liao, C. Y.; Liao, C. J.; Cheng, W. L.; Chen, W. J.; Lin, K. H., Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. J. Mol. Endocrinol., 2006, 36 (1), 9-21.
238. Martinez-Iglesias, O.; Garcia-Silva, S.; Tenbaum, S. P.; Regadera, J.; Larcher, F.; Paramio, J. M.; Vennstrom, B.; Aranda, A., Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res., 2009, 69 (2), 501-509.
239. Perra, A.; Kowalik, M. A.; Pibiri, M.; Ledda-Columbano, G. M.; Columbano, A., Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology, 2009, 49 (4), 1287-1296.
240. Liao, C. S.; Tai, P. J.; Huang, Y. H.; Chen, R. N.; Wu, S. M.; Kuo, L. W.; Yeh, C. T.; Tsai, M. M.; Chen, W. J.; Lin, K. H., Regulation of AKR1B1 by thyroid hormone and its receptors. Mol. Cell Endocrinol., 2009, 307 (1-2), 109-117.
241. Wu, S. M.; Huang, Y. H.; Lu, Y. H.; Chien, L. F.; Yeh, C. T.; Tsai, M. M.; Liao, C. H.; Chen, W. J.; Liao, C. J.; Cheng, W. L.; Lin, K. H., Thyroid hormone receptor-mediated regulation of the methionine adenosyltransferase 1 gene is associated with cell invasion in hepatoma cell lines. Cell Mol. Life Sci., 2010, 67 (11), 1831-1843.
242. Margolis, R. N.; Christakos, S., The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation. An update. Ann. N Y Acad. Sci., 2010, 1192, 208-214.
243. Verhave, G.; Siegert, C. E., Role of vitamin D in cardiovascular disease. Neth. J. Med., 2010, 68 (3), 113-118.
244. McCullough, M. L.; Bostick, R. M.; Mayo, T. L., Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr., 2009, 29, 111-132.
245. Zinser, G. M.; Suckow, M.; Welsh, J., Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid. Biochem. Mol. Biol., 2005, 97 (1-2), 153-164.
246. Falleti, E.; Bitetto, D.; Fabris, C.; Cussigh, A.; Fontanini, E.s; Fornasiere, E.; Fumolo, E.; Bignulin, S.; Cmet, S.; Minisini, R.; Pirisi, M.; Toniutto, P., Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J. Gastroenterol., 2010, 16 (24), 3016-3024.